Professor Evis Sala

University departments
Department of Radiology
NHS or other affiliations
Honorary Consultant Radiologist

Position: Ex-Professor of Oncological Imaging
Personal home page:

PubMed journal articles - click here

Research description

Now based in Rome, my research in Cambridge focused on integrated diagnostics, through the clinical development and validation of functional imaging biomarkers to rapidly evaluate treatment response using physiologic and metabolic tumour habitat imaging. My research in the new field of “radio genomics” has focused on understanding the molecular basis of cancer by demonstrating the phenotypic patterns which occur as a result of multiple genetic alterations that interact with the tumour microenvironment to drive the disease. My work integrates quantitative imaging methods for evaluation of spatial and temporal tumour heterogeneity with genomics, proteomics and metabolomics. The integration of “multi-omics” data will be essential for unravelling tumour heterogeneity and making real-time clinical decisions for patients.
I am one of the two programme leads for the Advanced Cancer Imaging programme.
I am active in many academic organizations. I am the Chair of Radiology Society of North America (RSNA) Oncologic Imaging Track, serve on the Oncologic Imaging and Therapies Task Force of RSNA and the Genitourinary Imaging Subcommittee of European Society of Radiology. I am a member of Board of Trustees of the International Society for Magnetic Resonance in Medicine (ISMRM), the International Cancer Imaging Society (ICIS) and The European Society of Urogenital Radiology (ESUR). I am an Editorial Board member and Head of Oncology Section of European Radiology. I was elected as a Fellow of ICIS in 2014, a Fellow of ISMRM in 2015, a fellow of ESUR in 2018 and received the RSNA Honoured Educator Award in 2014 and 2017. I was recently given the 2020 BIR/Canon Mayneord Award.

Research Programme or Virtual Institute
Advanced Cancer Imaging
Secondary Programme
Ovarian Cancer
Strategic Resources
The Mark Foundation Institute for Integrated Cancer Medicine: Re-inventing the patient pathway
Methods and technologies
Clinical trials
Magnetic Resonance Imaging (MRI)
Tumour type interests
Uterus and unspecified
Cancer imaging
ovarian cancer
Recent publications:
 Retrieving latest data from feed...

Symplectic Elements feed provided by Research Information, University of Cambridge

Key publications

•Sala E, Kataoka MY, Priest AN, Gill AB, McClean MA, Joubert I, Graves MJ, Crawford R, Jimenez-Linan M, Earl H, Hodgkin C, Griffiths JR, Lomas DJ, Brenton JD. Advanced Ovarian Cancer: Multiparametric MR Imaging Demonstrates Response- and Metastasis-specific Effects. Radiology 2012 Apr; 263(1):149-159.
•Vargas HA, Micco M, Hong S, Goldman DA, Dao, F, Weigelt B, Soslow RA, Hricak H, Levine DA, Sala E. Association between morphologic computed tomography imaging traits and prognostically relevant gene signatures in women with high-grade serous ovarian cancer: A Hypothesis Generating Study. Radiology. 2015 Mar; 274(3):742-51
•Lakhman Y, Veeraraghavan H, Chaim J, Feier D, Goldman DA, Moskowitz CS, Nougaret S, Sosa RE, Vargas HA, Soslow R, Hricak H, Abu-Rustum NR, Sala E. Differentiation of Uterine leiomyosarcoma from atypical leiomyoma: diagnostic accuracy of qualitative MR imaging features and role of texture analysis. Eur Radiol 2016 PMID: 27921159 DOI:10.1007/s00330-016-4623-9.
•Parkinson CA, Gale D, Piskorz AM, Biggs H, Hodgkin C, Addley H, Freeman S, Moyle P, Sala E, Sayal K, Hosking K, Gounaris I, Jimenez-Linan M, Earl HE, Qian W, Rosenfeld N, Brenton JD. Exploratory analysis of TP53 mutations in circulating tumour DNA as biomarkers of treatment response for patients with relapsed high-grade serous ovarian carcinoma: a retrospective analysis. PLoS Med 2016 Dec 20;13(12):e1002198. doi:10.1371/journal.pmed.1002198.
•Jiménez-Sánchez A, Memmon D, Pourpe S, Veeraraghavan H, Li Y, Vargas HA, Gill MB, Park KJ, Zivanovic O, Konner J, Ricca J, Zamarin D, Walther T, Aghajanian C, Wolchok J, Sala E, Merghoub T, Snyder A, Miller ML. Heterogeneous tumor-immune microenvironments among differentially growing metastases in an ovarian cancer patient. Cell 2017;170(5):927-938.e920
•Nougaret, S., Lakhman, Y., Molinari, N., Feier, D., Scelzo, C., Vargas, H. A., … Sala, E. (2018). CT features of ovarian tumors: Defning key differences between serous borderline tumors and low-grade serous carcinomas. American Journal of Roentgenology, 210(4), 918–926.